7-(4-(6-Chloro-1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidin-1-yl)-1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid | 1018937-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-(4-(6-Chloro-1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidin-1-yl)-1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid
• 英文别名: 7-[4-(5-chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid
• CAS: 1018937-91-1
• 化学式: C₂₆H₂₃ClFN₅O₇
• 分子量: 571.949
• InChiKey: LVYBGAZDRQRBAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  40
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  148
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-cyclopropyl-6,7-difluoro-1,4-dihydro-5-nitro-8-methoxy-4-oxoquinoline-3-carboxylic acid 、 5-氯-1,3-二氢-1-(4-哌啶基)-2H-苯并咪唑-2-酮 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.03h， 以78%的产率得到7-(4-(6-Chloro-1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)piperidin-1-yl)-1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids

  摘要：

  Thirty-four newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids were synthesized from 1,2,3,4-tetrafluoro benzene and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MT13), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium sinegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase. Among the synthesized compounds, 7-(1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydroisoquinolin-2(1H)-yl)-1-cyclopropy1-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid (13n) was found to be the most active compound in vitro with MIC of 0.16 and 0.33 mu M against MT13 and MDR-TB, respectively. In the in vivo animal model 13n decreased the bacterial load in lung and spleen tissues with 2.54 and 2.92 - log 10 protections, respectively, at the dose of 50 mg/kg body weight. Compound 13n also inhibited the supercoiling activity of mycobacterial DNA gyrase with IC50 of 30.0 mu g/ml. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.050

文献信息

• Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids
  作者：Palaniappan Senthilkumar、Murugesan Dinakaran、Debjani Banerjee、Ruth Vandana Devakaram、Perumal Yogeeswari、Arnab China、Valakunja Nagaraja、Dharmarajan Sriram

  DOI：10.1016/j.bmc.2007.11.050

  日期：2008.3

  Thirty-four newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids were synthesized from 1,2,3,4-tetrafluoro benzene and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MT13), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium sinegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase. Among the synthesized compounds, 7-(1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydroisoquinolin-2(1H)-yl)-1-cyclopropy1-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxoquinoline-3-carboxylic acid (13n) was found to be the most active compound in vitro with MIC of 0.16 and 0.33 mu M against MT13 and MDR-TB, respectively. In the in vivo animal model 13n decreased the bacterial load in lung and spleen tissues with 2.54 and 2.92 - log 10 protections, respectively, at the dose of 50 mg/kg body weight. Compound 13n also inhibited the supercoiling activity of mycobacterial DNA gyrase with IC50 of 30.0 mu g/ml. (C) 2007 Elsevier Ltd. All rights reserved.